^
    Back
    Association details:
    Biomarker:ERBB3 overexpression
    Cancer:Triple Negative Breast Cancer
    Drug Class:HDAC inhibitor +
    AKT1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2022
    Title:

    2969 / 17 - Histone deacetylase (HDAC) inhibitors exhibit antitumor activity in triple negative breast cancer via suppression of HER3 triggered signaling

    Published date:
    03/09/2022
    Excerpt:
    Elevated expression of HER3 were observed in approximately half of the TNBC specimens and cell lines tested....HDACis in combination with an EGFR inhibitor (gefitinib) or an Akt inhibitor (Akti1/2) synergistically enhanced the anti-survival effects on HER3high-TNBC cells.